MedTrace Logo

Autologous Endothelial Progenitor Cells Transplantation for Chronic Ischemic Stroke

NCT02605707 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2021-04-02

No results posted yet for this study

Summary

Stroke is a frequently occurring and common diseases in nervous system,and most of the survivors will remain disorders of motor,sensory and cognition function.Stem cell transplantation provides a promising approach for rehabilitation. The main objective of this study is to evaluate the efficacy and safy of the transplantation of autologous endothelial progenitor cells in patients with chronic stroke.

Conditions

Interventions

DRUG

Intravenous stem cell transplantation

Intravenous injection of autologous endothelial progenitor cells transplantation

Sponsors & Collaborators

  • Second Affiliated Hospital of Guangzhou Medical University

    collaborator OTHER

  • Southern Medical University, China

    lead OTHER

Principal Investigators

  • ZhenZhou Chen, MD, phD · Department of Neurosurgery, Zhujiang Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2017-12-31
Completion
2020-02-29

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02605707 on ClinicalTrials.gov